Span Divergent Limited , formerly known as Span Diagnostics Limited, has announced several significant corporate actions following its board meeting on November 10, 2025. The company has made strategic decisions aimed at streamlining its operations and strengthening its financial position.

Divestment of Subsidiary Stake

The board has approved the sale of Span Divergent's entire 99% stake in its subsidiary, Span Diagnostics LLP, to promoters Mr. Viral P Desai and Ms. Sujata V Desai for INR 99,000. This decision comes after shareholders approved the transaction on September 26, 2024. The subsidiary has been inoperative since its inception and contributed no income or net worth during the financial year 2024-2025.

Despite the buyers being part of the promoter group, the company stated that the transaction is being conducted at arm's length price.

Exploration of Fund-Raising Options

Span Divergent's board has approved the exploration of various fund-raising avenues to bolster its financial position and support future growth initiatives. The company is considering options including a Fresh Public Offer (FPO), Preferential Allotment, or other appropriate modes.

The management has been authorized to evaluate alternatives, assess market conditions, and engage professional advisors and merchant bankers to assist in the process. However, the company emphasized that no definitive decision has been made regarding the structure, size, or timing of any proposed fund-raising at this stage.

Board and Management Changes

The company announced several changes to its board composition:

1. Appointment of Mr. Dharmesh Vinodbhai Desai as an Additional Non-Executive Independent Director for a five-year term, subject to shareholder approval.
2. Resignation of Mr. Nirav Dineshchandra Jogani as an Independent Director.
3. Resignation of Dr. Pradipkumar Keshavlal Desai as Non-Executive and Non-Independent Director, who will continue as "Chairman Emeritus" in an advisory role.

Subsidiary Operations

The board has approved a plan to revive operations of its subsidiary, M/s. Aranya Agri Biotech LLP, reclassifying its assets as part of Property, Plant and Equipment (PPE) in light of new business opportunities.

Financial Performance

For the quarter ended September 30, 2025, Span Divergent reported the following consolidated results:

The company's revenue saw a significant increase, but it reported a loss compared to a profit in the same quarter of the previous year.

These strategic moves and financial results reflect Span Divergent's efforts to optimize its corporate structure and explore growth opportunities amidst challenging market conditions.

Span Divergent Limited, formerly known as Span Diagnostics Limited, has announced its unaudited financial results for the first quarter. The company's performance shows a mixed picture, with improved standalone results but challenges in its consolidated financials.

Standalone Performance

On a standalone basis, Span Divergent reported a significant improvement in its bottom line. The company's profit after tax increased to Rs 41.67 crore, up from Rs 23.08 crore in the same quarter last year. This represents an impressive year-over-year growth of 80.50%. The basic earnings per share (EPS) also saw a substantial rise, reaching Rs 0.76 compared to Rs 0.42 in the previous year's corresponding quarter.

However, the total income for the quarter decreased to Rs 64.93 crore from Rs 73.55 crore in the corresponding period of the previous year, marking a decline of 11.72%.

Consolidated Results

The consolidated financial results paint a different picture. Span Divergent reported a consolidated loss after tax of Rs 17.01 crore, compared to a loss of Rs 8.53 crore in the same quarter of the previous year. This indicates a widening of losses at the group level.

Segment Performance

Span Divergent operates across three main segments:

1. Cashew processing
2. Tissue culture
3. Trading

The segment-wise performance is as follows:

Subsidiary Challenges

Several of Span Divergent's subsidiaries are facing financial difficulties:

• Aranya Agri Biotech LLP has accumulated losses of Rs 15.12 crore. The Board has approved a plan to discontinue its operations, and its assets have been classified as held for sale since September 30, 2023.

• Biospan Contamination Control Solutions Pvt Ltd reported accumulated losses of Rs 6.54 crore. The company's total liabilities exceeded its total assets by Rs 6.35 crore as of March 31.

Despite these challenges, the management remains optimistic about turning around these subsidiaries. They are exploring possibilities to revive Biospan Scientific LLP and are confident that Biospan Contamination Control Solutions Pvt Ltd can establish profitable operations with appropriate product introductions.

Financial Position

Span Divergent maintains a relatively strong financial position with no outstanding loans from banks or financial institutions. The company only has Rs 1.92 crore in unsecured loans from directors.

The Board of Directors approved these unaudited financial results at their meeting held on August 13. As the company navigates through the challenges in its subsidiaries and segments, investors will be watching closely to see if the positive standalone performance can translate into improved consolidated results in the coming quarters.